- Home
- ABTS vs APLM Comparison
ABTS vs APLM Comparison
Compare ABTS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- APLM
- Stock Information
- Founded
- ABTS 2010
- APLM 2016
- Country
- ABTS Hong Kong
- APLM United States
- Employees
- ABTS N/A
- APLM N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- APLM Blank Checks
- Sector
- ABTS Technology
- APLM Finance
- Exchange
- ABTS Nasdaq
- APLM Nasdaq
- Market Cap
- ABTS 9.8M
- APLM 6.9M
- IPO Year
- ABTS N/A
- APLM N/A
- Fundamental
- Price
- ABTS $5.88
- APLM $5.33
- Analyst Decision
- ABTS
- APLM
- Analyst Count
- ABTS 0
- APLM 0
- Target Price
- ABTS N/A
- APLM N/A
- AVG Volume (30 Days)
- ABTS 49.3K
- APLM 26.7K
- Earning Date
- ABTS 08-16-2025
- APLM 08-13-2025
- Dividend Yield
- ABTS N/A
- APLM N/A
- EPS Growth
- ABTS N/A
- APLM N/A
- EPS
- ABTS N/A
- APLM N/A
- Revenue
- ABTS $6,711,225.00
- APLM $198,000.00
- Revenue This Year
- ABTS N/A
- APLM $415.15
- Revenue Next Year
- ABTS N/A
- APLM N/A
- P/E Ratio
- ABTS N/A
- APLM N/A
- Revenue Growth
- ABTS 299.11
- APLM N/A
- 52 Week Low
- ABTS $1.35
- APLM $4.47
- 52 Week High
- ABTS $14.10
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- ABTS 68.00
- APLM 44.49
- Support Level
- ABTS $4.11
- APLM $5.33
- Resistance Level
- ABTS $5.39
- APLM $6.56
- Average True Range (ATR)
- ABTS 0.59
- APLM 0.54
- MACD
- ABTS 0.11
- APLM -0.05
- Stochastic Oscillator
- ABTS 93.38
- APLM 33.11
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.